Handl Therapeutics

Foundation date

01/10/2019

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

The vision at the heart of Handl is to deploy the power of disease modifying in vivo gene therapy towards the treatment of complex neurodegenerative diseases and thereby to begin addressing significant unmet medical needs in current and future healthcare.

Upcoming events

Latest news

  • Mithra announces topline results for COVID-19 Phase II Study

    1 day ago

  • Biocartis announces restart of its high-throughput cartridge manufacturing line

    Thursday September 23rd 2021

  • Rewind Therapeutics appoints Anja Harmeier, PhD, MBA, as Chief Executive Officer

    Wednesday September 22nd 2021

Jobs by Handl Therapeutics